Age Related Vision Dysfunction Market is expected to be worth US$ 130 billion by 2033 | FMI

 A recently published study by FMI expects the global Age-Related Vision Dysfunction Market to augment at a 3.7% CAGR from 2023 to 2033. By the end of the said assessment period, a valuation of US$ 130 Billion is expected for the market. The rising incidence of visual impairment and blindness is a primary driver of the global age related vision dysfunction market's expansion.

Full Information Source @ https://www.futuremarketinsights.com/reports/age-related-vision-dysfunction-market

Furthermore, the rising prevalence of eye illnesses such as diabetic, glaucoma, cataract, and age-related macular degeneration is expected to boost demand for assistive technology in age related vision dysfunction. As a result, the worldwide age related vision dysfunction market will expand. For example, the World Glaucoma Association estimates that 79.6 million people would develop glaucoma by 2020. This figure is expected to rise to 111.8 million by 2040.

Age Related Vision Dysfunction market

According to a United Nations (UN) estimate, the worldwide population of people aged 60 and more was around 962 million in 2017, with a projected increase to 2.1 billion by 2050 According to the National Federation of the Blind, an estimated 3,171,100 persons aged 65 and older in the United States had visual impairment in 2016. All these factors are likely to drive the age-related vision dysfunction market during the forecast period

Key Takeaways from the Market Study

  • FMI projects the global Age Related Vision Dysfunction market to expand at a 3.7% value CAGR by 2033
  • The global Age Related Vision Dysfunction market is estimated at a market value of US$ 90 Billion
  • The global Age Related Vision Dysfunction market is expected to garner a market value of US$ 130 Billion
  • As per Future Market Insights, Asia Pacific is expected to grow at a CAGR of 3.5% in the assessment period 2023-2033.
  • As per Future Market Insights, North America is expected to grow at a CAGR of 3.6% in the assessment period 2023-2033.
  • As per Future Market Insights, Europe is expected to grow at a CAGR of 3.3% in the assessment period 2023-2033.
  • The glaucoma segment is expected to hold the largest market share for Age Related Vision Dysfunction in the forecast period 2023-2033

 “Increased government measures to develop assistive technology and supply assistive technology equipment to the disabled is also predicted to fuel growth in the worldwide age related vision dysfunction market.”Says an analyst at FMI

Market Competition

  • Aerie Pharmaceuticals
  • Santen Pharmaceutical
  • Sun Pharma Advanced Research Company Limited
  • Bausch + Lomb
  • D Western Therapeutics Institute
  • Novartis
  • AbbVie
  • Eyenovia
  • Orasis Pharmaceuticals
  • IVERIC Bio

Recent Developments:

  • In May 2020, AbbVie Inc. finalised the strategic acquisition of Allergan plc. As a result of this purchase, AbbVie Inc. has positioned itself as a market leader in the age related vision dysfunction

Key Segments Profiled in the Age Related Vision Dysfunction Market Industry Survey

Age Related Vision Dysfunction Market by Dysfunction Type:

  • Cataract
  • AMD
  • Glaucoma
  • Presbyopia

Age Related Vision Dysfunction Market by Drug:

  • Rocklatan
  • Eybelis Ophthalmic Solution
  • Xelpros
  • Rhopressa
  • Vyzulta
  • Glanatec
  • Simbrinza
  • Tapcom/DE-111
  • Azarga/Azorga
  • Combigan
  • Lucentis
  • Eylea
  • Beovu

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more